Figure 8. Proposed mechanism of action for Diapin to lower blood glucose in T2D.

Diapin is a tripeptide that has potential to treat T2D. Oral administration of Diapin may directly act on enteroendocrine L-cells in gastrointestinal tract to stimulate GLP-1 secretion (dashed line: unknown mechanisms), which in turn stimulates the glucose-dependent insulin secretion. In addition, Diapin in the blood stream may also act on pancreatic β-cells to stimulate insulin secretion (dashed line: unknown mechanisms). This dual effect leads to the elevation of insulin and the effective control of blood glucose in T2D.